Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy
Source: SeekingAlpha
2026-06-06 10:09:29 ET
More on Pfizer
- Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
- Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A Efforts - Reiterate Buy
- FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer
- Three studies used to justify U.S. vaccine policy under RFK Jr. face scrutiny: Guardian
- Pfizer in pact with Chai Discovery to use AI platform in drug development
Read the full article on Seeking Alpha
For further details see:
Pfizer says mid-stage trial data support monthly dosing for GLP-1 therapy
Novo Nordisk A/S
NASDAQ: NVO
NVO Trading
-0.76% G/L:
$49.165 Last:
5,468,354 Volume:
$49.17 Open:
NVO Latest News
July 11, 2026 09:35:00 am
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
July 10, 2026 07:35:00 pm
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
$220,548,675,000
4,194,421,000
N/A
749
N/A
Biotechnology & Life Sciences
Healthcare
DK
Bagsvaerd
